Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Targovax ASA ( (GB:0RIS) ) is now available.
Circio Holding ASA announced that their abstract on the circVec expression platform has been selected for presentation at the prestigious ESGCT annual meeting. The presentation will highlight the advantages of circVec-AAV in enhancing gene and cell therapy, showcasing statistically significant improvements in expression across multiple tissues. This development positions Circio as a leader in the field, potentially setting a new standard for gene expression technology.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing circular RNA vector expression technology for next-generation nucleic acid medicine. Their proprietary circVec platform is designed for efficient biogenesis of multifunctional circRNA inside target cells, offering potential applications in genetic medicine, cell therapy, and chronic disease. The platform has demonstrated significant improvements in RNA half-life and protein expression compared to conventional systems.
Average Trading Volume: 352,903
Current Market Cap: NOK66.39M
See more data about 0RIS stock on TipRanks’ Stock Analysis page.